Cargando…

Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study

BACKGROUND & OBJECTIVES: Vaccination against SARS-CoV-2 is a recommendation from the World Health Organization as the foremost preference in the current situation to control the COVID-19 pandemic. BBV152 is one of the approved vaccines against SARS-CoV-2 in India. In this study, we determined SA...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Nathella Pavan, Padmapriyadarsini, C., Uma Devi, K. R., Banurekha, V. V., Nancy, Arul, Girish Kumar, C. P., Murhekar, Manoj V., Gupta, Nivedita, Panda, Samiran, Babu, Subash, Bhargava, Balram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555618/
https://www.ncbi.nlm.nih.gov/pubmed/34528524
http://dx.doi.org/10.4103/ijmr.IJMR_2066_21
_version_ 1784592014993522688
author Kumar, Nathella Pavan
Padmapriyadarsini, C.
Uma Devi, K. R.
Banurekha, V. V.
Nancy, Arul
Girish Kumar, C. P.
Murhekar, Manoj V.
Gupta, Nivedita
Panda, Samiran
Babu, Subash
Bhargava, Balram
author_facet Kumar, Nathella Pavan
Padmapriyadarsini, C.
Uma Devi, K. R.
Banurekha, V. V.
Nancy, Arul
Girish Kumar, C. P.
Murhekar, Manoj V.
Gupta, Nivedita
Panda, Samiran
Babu, Subash
Bhargava, Balram
author_sort Kumar, Nathella Pavan
collection PubMed
description BACKGROUND & OBJECTIVES: Vaccination against SARS-CoV-2 is a recommendation from the World Health Organization as the foremost preference in the current situation to control the COVID-19 pandemic. BBV152 is one of the approved vaccines against SARS-CoV-2 in India. In this study, we determined SARS-CoV-2–specific antibody levels at day 0 (baseline, before vaccination), day 28 ± 2 post-first dose (month 1) and day 56 ± 2 post-first dose (month 2) of BBV152 whole-virion–inactivated SARS-CoV-2 recipients, and compared the antibody responses of individuals with confirmed pre-vaccination SARS-CoV-2 infection to those individuals without prior evidence of infection. METHODS: Blood samples were collected from 114 healthcare professionals and frontline workers who received BBV152 vaccine from February to May & June 2021. Prior infection with SARS-CoV-2 was determined at baseline. Serum samples were used to estimate SARS-CoV-2 nucleoprotein-specific IgG [IgG (N)], spike protein-specific IgG [IgG (S)] and neutralizing antibodies (NAb). RESULTS: Participants with previous SARS-CoV-2 infection after a single vaccine dose elicited IgG (N) and IgG (S) antibody levels along with NAb binding inhibition responses levels were similar to infection-naïve vaccinated participants who had taken two doses of vaccine. INTERPRETATION & CONCLUSIONS: Our preliminary data suggested that a single dose of BBV152-induced humoral immunity in previously infected individuals was equivalent to two doses of the vaccine in infection-naïve individuals. However, these findings need to be confirmed with large sized cohort studies.
format Online
Article
Text
id pubmed-8555618
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-85556182021-11-09 Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study Kumar, Nathella Pavan Padmapriyadarsini, C. Uma Devi, K. R. Banurekha, V. V. Nancy, Arul Girish Kumar, C. P. Murhekar, Manoj V. Gupta, Nivedita Panda, Samiran Babu, Subash Bhargava, Balram Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Vaccination against SARS-CoV-2 is a recommendation from the World Health Organization as the foremost preference in the current situation to control the COVID-19 pandemic. BBV152 is one of the approved vaccines against SARS-CoV-2 in India. In this study, we determined SARS-CoV-2–specific antibody levels at day 0 (baseline, before vaccination), day 28 ± 2 post-first dose (month 1) and day 56 ± 2 post-first dose (month 2) of BBV152 whole-virion–inactivated SARS-CoV-2 recipients, and compared the antibody responses of individuals with confirmed pre-vaccination SARS-CoV-2 infection to those individuals without prior evidence of infection. METHODS: Blood samples were collected from 114 healthcare professionals and frontline workers who received BBV152 vaccine from February to May & June 2021. Prior infection with SARS-CoV-2 was determined at baseline. Serum samples were used to estimate SARS-CoV-2 nucleoprotein-specific IgG [IgG (N)], spike protein-specific IgG [IgG (S)] and neutralizing antibodies (NAb). RESULTS: Participants with previous SARS-CoV-2 infection after a single vaccine dose elicited IgG (N) and IgG (S) antibody levels along with NAb binding inhibition responses levels were similar to infection-naïve vaccinated participants who had taken two doses of vaccine. INTERPRETATION & CONCLUSIONS: Our preliminary data suggested that a single dose of BBV152-induced humoral immunity in previously infected individuals was equivalent to two doses of the vaccine in infection-naïve individuals. However, these findings need to be confirmed with large sized cohort studies. Wolters Kluwer - Medknow 2021 /pmc/articles/PMC8555618/ /pubmed/34528524 http://dx.doi.org/10.4103/ijmr.IJMR_2066_21 Text en Copyright: © 2021 Indian Journal of Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Kumar, Nathella Pavan
Padmapriyadarsini, C.
Uma Devi, K. R.
Banurekha, V. V.
Nancy, Arul
Girish Kumar, C. P.
Murhekar, Manoj V.
Gupta, Nivedita
Panda, Samiran
Babu, Subash
Bhargava, Balram
Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
title Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
title_full Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
title_fullStr Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
title_full_unstemmed Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
title_short Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
title_sort antibody responses to the bbv152 vaccine in individuals previously infected with sars-cov-2: a pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555618/
https://www.ncbi.nlm.nih.gov/pubmed/34528524
http://dx.doi.org/10.4103/ijmr.IJMR_2066_21
work_keys_str_mv AT kumarnathellapavan antibodyresponsestothebbv152vaccineinindividualspreviouslyinfectedwithsarscov2apilotstudy
AT padmapriyadarsinic antibodyresponsestothebbv152vaccineinindividualspreviouslyinfectedwithsarscov2apilotstudy
AT umadevikr antibodyresponsestothebbv152vaccineinindividualspreviouslyinfectedwithsarscov2apilotstudy
AT banurekhavv antibodyresponsestothebbv152vaccineinindividualspreviouslyinfectedwithsarscov2apilotstudy
AT nancyarul antibodyresponsestothebbv152vaccineinindividualspreviouslyinfectedwithsarscov2apilotstudy
AT girishkumarcp antibodyresponsestothebbv152vaccineinindividualspreviouslyinfectedwithsarscov2apilotstudy
AT murhekarmanojv antibodyresponsestothebbv152vaccineinindividualspreviouslyinfectedwithsarscov2apilotstudy
AT guptanivedita antibodyresponsestothebbv152vaccineinindividualspreviouslyinfectedwithsarscov2apilotstudy
AT pandasamiran antibodyresponsestothebbv152vaccineinindividualspreviouslyinfectedwithsarscov2apilotstudy
AT babusubash antibodyresponsestothebbv152vaccineinindividualspreviouslyinfectedwithsarscov2apilotstudy
AT bhargavabalram antibodyresponsestothebbv152vaccineinindividualspreviouslyinfectedwithsarscov2apilotstudy